Maravai LifeSciences Holdings Inc MRVI.OQ MRVI.O is expected to show a fall in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024
The San Diego California-based company is expected to report a 22.7% decrease in revenue to $57.345 million from $74.14 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
LSEG's mean analyst estimate for Maravai LifeSciences Holdings Inc is for a loss of 4 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $9.25, above its last closing price of $2.84.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.01 | -0.01 | -0.02 | Missed | -160.1 |
Jun. 30 2024 | 0.00 | 0.00 | 0.00 | Met | -100 |
Mar. 31 2024 | -0.03 | -0.03 | -0.02 | Beat | 21.4 |
Dec. 31 2023 | -0.01 | -0.01 | 0.01 | Beat | 184.6 |
Sep. 30 2023 | 0.00 | 0.01 | -0.01 | Missed | -257.2 |
Jun. 30 2023 | 0.01 | 0.01 | 0.00 | Missed | -100 |
Mar. 31 2023 | 0.04 | 0.04 | 0.03 | Missed | -17.2 |
Dec. 31 2022 | 0.35 | 0.34 | 0.35 | Beat | 2.4 |
This summary was machine generated March 5 at 21:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。